{"filing":{"accession_number":"0001104659-26-078327","cik":"0001133869","ticker":"CAPR","company_name":"CAPRICOR THERAPEUTICS, INC.","form":"8-K","filing_date":"2026-06-26","report_date":null,"primary_document":"capr-20260626x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1133869/000110465926078327/capr-20260626x8k.htm"},"events":[{"id":14353,"run_id":12778,"accession_number":"0001104659-26-078327","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Capricor announced that the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee will convene on July 29, 2026 to review the company's Biologics License Application (BLA) for Deramiocel, with a PDUFA target action date of August 22, 2026. This is a material regulatory milestone in the development of the company's lead product candidate for Duchenne muscular dystrophy, representing a significant step toward potential FDA approval. While not a completed approval or a specific operational event like a partnership or contract, this is a material regulatory development that would affect investor assessment of the company's near-term prospects.","company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","filing_date":"2026-06-26","form":"8-K","submitted_at":null,"items":[{"id":11748,"accession_number":"0001104659-26-078327","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Capricor announced that the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee will convene on July 29, 2026 to review the company's Biologics License Application (BLA) for Deramiocel, with a PDUFA target action date of August 22, 2026. This is a material regulatory milestone in the development of the company's lead product candidate for Duchenne muscular dystrophy, representing a significant step toward potential FDA approval. While not a completed approval or a specific operational event like a partnership or contract, this is a material regulatory development that would affect investor assessment of the company's near-term prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-26T21:16:41.793957+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11748,"accession_number":"0001104659-26-078327","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Capricor announced that the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee will convene on July 29, 2026 to review the company's Biologics License Application (BLA) for Deramiocel, with a PDUFA target action date of August 22, 2026. This is a material regulatory milestone in the development of the company's lead product candidate for Duchenne muscular dystrophy, representing a significant step toward potential FDA approval. While not a completed approval or a specific operational event like a partnership or contract, this is a material regulatory development that would affect investor assessment of the company's near-term prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-26T21:16:41.793957+00:00","company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","filing_date":"2026-06-26"}]}